Good morning, everyone, and nice to see you again. We hope the weekend was fun and refreshing. Now, of course, the routine of meetings and deadlines has resumed. We can relate. To cope, we our quaffing our mandatory cup of stimulation and invite you to join us on this sunny morning. After all, there is much work to be done. To help you get started, here are some tidbits from around the world. Have a good one and stay in touch....
EU Widens Safety Review Of Sanofi's Multaq (Reuters)
A Scramble For Death Penalty Drug As Supply Tightens (Associated Press)
Sanofi Sells Dermatology Unit To Valeant Pharma For $425 Million (Outsourcing Pharma)
India Planning Commissions Denies Move To Restrict Foreign Investment (Economic Times)
Pharma Tries To Sidetrack Demands For Medicare Discounts (Los Angeles Times)
Sanofi MS Drug Gets Mixed Results (The Street)
Amgen And Micromet Sign Cancer Drug Deal (Reuters)
Teva & Merck Reach Deal To Delay Generic Vytorin Until 2017 (Bloomberg News)
Glaxo CEO Witty: The West Must Be Competiting In Manufacturing (The Globe & Mail)
Pfizer EU Patent For Lipitor Is Extended For Pediatric Tests (Financial Times)
South Africa Urges Bristol-Myers To Prevent AIDS Drug Shortage (PharmaTechnology)
Orchid API Plant Receives Closure Notice (MoneyControl)
FDA Approves Glaxo Combo Vaccine For Seniors (Bloomberg News)
FDA To Hold Panel To Review Safety Of Osteoporosis Meds (Dow Jones)
Pristine Pharma Vows Plant Will Open (Watertown Daily Times)
Abbott Sued Over Beetles In Baby Formula (Louisville Courier-Journal)
Prescription Drug Prices Soar In Vietnam (Vietnam News)
EDITOR'S NOTE: Please check this post for updates throughout the morning